Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer

BACKGROUND: The aim of our study was to retrospectively assess the incidence of interstitial lung disease (ILD) related to EGFR‐tyrosine kinase inhibitor (TKI) treatment immediately before and/or after the administration of a PD‐1 antibody. METHODS: We analyzed the data of 26 patients who underwent...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Thorac Cancer
Main Authors: Uchida, Takahiro, Kaira, Kyoichi, Yamaguchi, Ou, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Hashimoto, Kosuke, Nishihara, Fuyumi, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons Australia, Ltd 2019
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6449223/
https://ncbi.nlm.nih.gov/pubmed/30864291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13039
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki